The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global immunohematology market reached a value of US$ 2.1 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 6% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Immunohematology refers to a branch of medical sciences that studies blood and blood-forming tissues in relation to the immune system. It is used to study the presence of antigens in the blood and their reaction with antibodies that can either cause hemolysis or red blood cell (RBC) agglutination. Various immunohematology tests are conducted to ensure safe blood transfusion and prevent undesired immunity-, transplant-, and pregnancy-related reactions, and to diagnose blood related disorders and diseases such as HIV, Hepatitis, etc. They utilize various chemicals and devices, such as reagents, and automatic and semi-automatic analyzers that are based on the technology of microplates, biochips, gel cards, polymerase chain reaction and erythrocyte-magnetized technology (EMT).
The increasing prevalence of leukemia and other hematological disorders across the globe is one of the key factors driving the growth of the market. Furthermore, improvements in the healthcare infrastructure and the development of blood banks and trauma centers, especially in developing countries, is also providing a boost to the market growth. Increasing awareness among the masses regarding the activities associated with blood collection, processing, testing and storage has further created a positive impact on the demand for immunohematology devices. Additionally, various technological advancements, such as the development of innovative transfusion systems and fully-automated devices, are acting as other growth-inducing factors. These next-generation immunohematology devices aid in enhancing the efficacy of the diagnosis, minimizing analysis time and risk of human error, and providing emergency assistance to the patients. Other factors, including an increasing number of blood donation camps and awareness programs, along with improvements in the healthcare infrastructure, are projected to drive the market further.
Breakup by Product:
Breakup by Technology:
Breakup by Application:
Breakup by End-User:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbott, Antisel, BD (Becton Dickinson and Company), Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Grifols S.A., Merck KGaA, MTC Invitro Diagnostics AG, Ortho-Clinical Diagnostics Inc (The Carlyle Group), Siemens Healthcare GmbH, Thermo Fisher Scientific Inc., etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Product, Technology, Application, End-User, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbott, Antisel, BD (Becton Dickinson and Company), Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Grifols S.A., Merck KGaA, MTC Invitro Diagnostics AG, Ortho-Clinical Diagnostics Inc (The Carlyle Group), Siemens Healthcare GmbH and Thermo Fisher Scientific Inc.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at